Iovance Biotherapeutics (IOVA)
(Delayed Data from NSDQ)
$11.66 USD
+0.28 (2.46%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $11.66 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
IOVA 11.66 +0.28(2.46%)
Will IOVA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IOVA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IOVA
Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates
IOVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kronos Bio, Inc. (KRON) Expected to Beat Earnings Estimates: Should You Buy?
AquaBounty Technologies, Inc. (AQB) Reports Q2 Loss, Tops Revenue Estimates
Will Petrobras (PBR) Report Q2 Earnings Beat on Output Gains?
Other News for IOVA
Cellectis: Cheap With Promising But Speculative Cancer Therapies
Iovance Biotherapeutics put volume heavy and directionally bearish
October 11th Options Now Available For Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics call volume above normal and directionally bullish
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)